Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis.

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS European Cardiology Review Pub Date : 2023-02-01 DOI:10.15420/ecr.2022.10

Desak Ketut Sekar Cempaka Putri, Andrianto Andrianto, Makhyan Jibril Al-Farabi, Pandit Bagus Tri Saputra, Ricardo Adrian Nugraha

{"title":"Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis.","authors":"Desak Ketut Sekar Cempaka Putri, Andrianto Andrianto, Makhyan Jibril Al-Farabi, Pandit Bagus Tri Saputra, Ricardo Adrian Nugraha","doi":"10.15420/ecr.2022.10","DOIUrl":null,"url":null,"abstract":"<p><p>This article evaluates the efficacy of using ranolazine to improve diastolic performance and exercise capacity in heart failure with preserved ejection fraction. A comprehensive literature review found eight trials where there are no significant difference in peak O2 (p=0.09) and exercise duration (p=0.18) between ranolazine and placebo. The ranolazine group had significantly higher and better diastolic parameters compared to placebo, with a mean difference of 0.45 (95% CI [27.18-39.50]). There were no significant differences for haemodynamic parameters (blood pressure and heart rate) and electrocardiography (QT interval) between ranolazine and placebo. The review found that ranolazine has good wefficacy to improve diastolic performance among heart failure with preserved ejection fraction patients and it does not affect blood pressure, heart rate and rate of ventricular repolarisation (shortening of the QT interval).</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/d9/ecr-18-e02.PMC9947928.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Cardiology Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/ecr.2022.10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

This article evaluates the efficacy of using ranolazine to improve diastolic performance and exercise capacity in heart failure with preserved ejection fraction. A comprehensive literature review found eight trials where there are no significant difference in peak O2 (p=0.09) and exercise duration (p=0.18) between ranolazine and placebo. The ranolazine group had significantly higher and better diastolic parameters compared to placebo, with a mean difference of 0.45 (95% CI [27.18-39.50]). There were no significant differences for haemodynamic parameters (blood pressure and heart rate) and electrocardiography (QT interval) between ranolazine and placebo. The review found that ranolazine has good wefficacy to improve diastolic performance among heart failure with preserved ejection fraction patients and it does not affect blood pressure, heart rate and rate of ventricular repolarisation (shortening of the QT interval).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

雷诺嗪改善保留射血分数的心力衰竭患者舒张功能的疗效:一项系统综述和荟萃分析。

本文评价雷诺嗪对保留射血分数的心力衰竭患者舒张功能和运动能力的改善作用。一项全面的文献综述发现，在8项试验中，雷诺嗪和安慰剂在峰值氧含量(p=0.09)和运动时间(p=0.18)方面没有显著差异。雷诺嗪组舒张参数明显高于安慰剂组，平均差值为0.45 (95% CI[27.18-39.50])。雷诺嗪和安慰剂在血流动力学参数(血压和心率)和心电图(QT间期)方面无显著差异。本综述发现，雷诺嗪对保留射血分数的心力衰竭患者的舒张性能有良好的改善作用，且不影响血压、心率和心室复极率(缩短QT间期)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊